Who preaches water and drinks wine – Cardiovascular risk in a medical population in a project

Česká verzia

Authors: V. Musil ¹; J. Špinar ¹; Z. Pozdíšek ¹; O. Ludka ¹; P. Lokaj ¹; M. Felšöci ¹; M. Plachý ²; P. Balcárková ³; E. Janoušová ⁴; J. Jarkovský ⁴ ; T. Pavlík ⁴; D. Schwarz ⁴; L. Dušek ⁴
Authors place of work: Interní kardiologická klinika, FN a LF MU Brno ¹; II. interní klinika, FN u svaté Anny Brno a LF MU Brno ²; I. kardio-angiologická klinika, FN u svaté Anny Brno a LF MU Brno ³; Institut biostatistiky a analýz, LF MU Brno ⁴
Published in the journal: Kardiol Rev Int Med 2009, 11(4): 204-208
Category: Notice

Summary

Aim:
To evaluate the incidence of cardiovascular risk and metabolic syndrome in a population of physicians, secondary education health care professionals and other health care professionals.

Sample:
1176 respondents examined during the Czech Society of Cardiology, Czech Hypertension Society and Jan Evangelista Purkyne Society congresses in 2007 and 2008.

Results:
Based on the medical history, hypertension was present in 11.6%, diabetes mellitus or glucose tolerance disorder in 2.3%. Ideal weight was observed in 60.4% of respondents, hypercholesterolaemia in 28.6% and hypertriglyceridaemia in 27.7%. Optimal or normal systolic pressure was seen in just under 40% of respondents. The mean glucose level was 5.29 ± 1.0 mmol/l, total cholesterol 4.99 ± 1.27 mmol/l, HDL‑cholesterol 1.39 ± 0.45 mmol/l, LDL‑cholesterol 3.68 ± 1.19 mmol/l, triglycerides 1.52 ± 1.02 mmol/l. The target total cholesterol levels (according to the Czech Society of Cardiology guidelines) were achieved in 51.7% of men and 35.1% of women treated for hyperlipoproteinaemia. High cardiovascular risk was identified in 86 persons (7.3%). High cardiovascular risk at 60 years of age was identified in 233 individuals (19.8%). Criteria of metabolic syndrome according to IDF 2005 were fulfilled in 306 respondents (26.0%).

Conclusion:
High cardiovascular risk was calculated in 7.3 % of respondents, high cardiovascular risk at 60 years of age in almost 20% of respondents. There was no statistically significant difference between physicians and other health care professionals.

Key words:
heart score – metabolic syndrome – cardiovascular risk

Zdroje

1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world‑wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.

2. Špinar J, Vítovec J et al. Ischemická choroba srdeční. 1. vyd. Praha: Grada Publishing 2003.

3. Statistická ročenka ČR 2007. Praha: Český statistický úřad 2007.

4. Mayer O jr, Šimon J, Galovcová M et al. Úroveň sekundární prevence ischemické choroby srdeční u českách pacienců ve studii EUROASPIRE III. Cor Vasa 2008; 50: 156–162.

5. Task Force Members 2007 Guidelines for the Management of Arterial Hypertension. J Hypertension 2007; 25: 1105–1187.

6. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181–197.

7. Widimský J jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství 2008; 1: 101–118.

8. Expert Panel on Detection, Evaluation and Tratment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: finding from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.

10. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.

11. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries ; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.

12. De Backer G, Ambrossioni E, Borch‑Johnsen K et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention on clinical practice. Third joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601–1610.

13. Šimon J et al. Epidemiologie a prevence ischemické choroby srdeční. 1. vyd. Praha: Grada Publishing 2001.

14. Wood DA, Kotseva K, Connolly S et al. EUROACTION Study Group. Nurse‑coordinated multidisciplinary, family‑based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster‑randomised controlled trial. Lancet 2008; 371: 1999–2012.

15. Cífková R. Prevalence metabolického syndromu u reprezentativního vzorku české populace. ČIS Praha 2009; ústní sdělení.

16. Rosolová H. Metabolický syndrom ve vesnické populaci. ČIS Praha 2009; ústní sdělení.

17. Špinar J, Ludka O, Šenkyříková M et al. Hladiny cholesterolu v závislosti na věku. Vnitř lék 2009; 55 (9): 724–729.